TLR2 Antagonists for Glomerulonephritis Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glomerulonephritis, such as corticosteroids and non-steroidal anti-inflammatory drugs, have limitations including immune suppression, burdensome dialysis, and risks associated with transplantation, necessitating a targeted therapy that addresses inflammation in the glomerulus without these drawbacks.
Innovation Solution
Compounds that antagonize Toll-like Receptor 2 (TLR2) function by blocking ligand binding or intracellular signaling, using antibodies or other agents that specifically target TLR2 in kidney cells to reduce inflammation and prevent kidney damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If corticosteroids are used to treat glomerulonephritis, then inflammation is reduced, but immune suppression occurs
Solution Approach 1:
The patent applies local quality by targeting TLR2 specifically in the kidney glomerulus using localized administration or kidney-specific promoters, allowing anti-inflammatory effects to be concentrated where needed (in the inflamed glomeruli) while minimizing systemic immunosuppression. This spatial differentiation resolves the contradiction by making the therapeutic effect local rather than systemic.
Solution Approach 2:
The patent uses TLR2 as an intermediary target - rather than directly suppressing the immune system systemically, the therapy intervenes at the specific molecular level of TLR2 signaling in the kidney. This intermediary approach allows inflammation to be reduced through blocking a specific inflammatory pathway (TLR2) without triggering broad immune suppression, thus resolving the contradiction between effective anti-inflammatory action and preservation of immune function.
2Reliability
If conventional therapies are used, then glomerulonephritis is treated, but side effects and burdensome procedures occur
Solution Approach 1:
The patent extracts the essential therapeutic function (reducing inflammation in glomerulonephritis) from the complex conventional treatment regimen by identifying and targeting the specific molecular culprit - TLR2. This extraction allows the therapy to achieve treatment effectiveness through a single targeted mechanism rather than requiring multiple drugs and procedures, thereby reducing treatment burden while maintaining reliability.
Solution Approach 2:
The patent changes the fundamental parameter of treatment approach from non-specific systemic suppression to specific molecular targeting. By changing from a broad therapeutic parameter (systemic immunosuppression) to a precise molecular parameter (TLR2 inhibition), the therapy achieves effective treatment with reduced burden, as it addresses the root cause rather than requiring multiple symptomatic treatments.
3Object-affected harmful factors
If TLR2 is blocked to reduce inflammation, then kidney damage is prevented, but pathogen recognition may be affected
Solution Approach 1:
The patent applies local quality by restricting TLR2 blockade specifically to the kidney glomerulus, where inflammatory damage occurs. By localizing the inhibition to the site of pathology rather than systemically blocking TLR2 throughout the body, the therapy reduces inflammation where needed while preserving pathogen recognition capabilities in other tissues and organs, thus resolving the contradiction between anti-inflammatory efficacy and immune surveillance.
Solution Approach 2:
The patent applies partial action by selectively inhibiting TLR2 signaling only in the context of inflammatory kidney disease, rather than completely blocking TLR2 function systemically. This partial inhibition approach allows the therapy to reduce harmful inflammation in the kidney while leaving sufficient TLR2 activity intact for normal pathogen recognition and immune defense elsewhere in the body.
Data Source
AI summary
The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.